Alvaro Lopez, MD
Infectious Disease · Tucker, GANPI 1861440216
Payments from drug & device makers
Across 558 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$77K
- Merck$5K
- Janssen Products, LP$4K
- Theratechnologies Inc.$2K
- Viiv Healthcare Company$2K
- AbbVie$600
- plus $4K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 234 | $77,035 |
| Merck | 48 | $4,761 |
| Janssen Products, LP | 9 | $3,643 |
| Theratechnologies Inc. | 15 | $1,880 |
| Viiv Healthcare Company | 80 | $1,577 |
| AbbVie(2 entities) | 25 | $600 |
| Astellas Pharma US Inc | 13 | $569 |
| Cipla USA Inc. | 1 | $515 |
| Insmed, Inc. | 16 | $509 |
| Shionogi Inc | 20 | $485 |
| Johnson & Johnson | 29 | $328 |
| Melinta Therapeutics, LLC | 19 | $326 |
| La Jolla Pharmaceutical Company | 10 | $218 |
| Paratek Pharmaceuticals, Inc. | 10 | $210 |
| Pfizer | 7 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $131 |
| Smith+Nephew | 1 | $117 |
| Aimmune Therapeutics, Inc. | 3 | $64 |
| Grifols USA, LLC | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $41 |
| Biomerieux Inc | 1 | $40 |
| EMD Serono, Inc. | 2 | $37 |
| CSL Behring | 1 | $32 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $25 |
| Napo Pharmaceuticals Inc | 2 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Mylan Pharmaceuticals Inc. | 1 | $20 |
How this compares
$93,390 in reported general payments places this provider in the 80th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Tucker
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.